Technical Analysis for CGIX - Cancer Genetics, Inc.

Grade Last Price % Change Price Change
grade F 0.283 -8.71% -0.03
CGIX closed down 8.71 percent on Friday, January 18, 2019, on 1.86 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CGIX trend table...

Date Alert Name Type % Chg
Jan 18 Fell Below 20 DMA Bearish 0.00%
Jan 18 180 Bearish Setup Bearish Swing Setup 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Crossed Above 20 DMA Bullish -8.71%
Jan 17 MACD Bullish Signal Line Cross Bullish -8.71%
Jan 17 Stochastic Buy Signal Bullish -8.71%
Jan 17 Volume Surge Other -8.71%
Jan 17 Wide Bands Range Expansion -8.71%
Jan 17 Oversold Stochastic Weakness -8.71%

Older signals for CGIX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cancer Genetics, Inc., an early-stage diagnostics company, focuses on the development and commercialization of proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray test for the detection of chromosomal abnormalities observed in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and Diffuse Large B-cell Lymphoma; molecular testing to analyze DNA and RNA to follow progression of disease and response to therapy at the genetic level; cytogenetics testing, a series of methods for analyzing human chromosomes to identify malignancy; fish testing, an analysis of abnormalities at the chromosomal and gene levels; flow cytometry testing, an immuno pheno - type analysis of specific markers inside cells; histology testing, a microscopic examination of stained tissue sections; cytology testing, a non-gynecological fluid preparation for microscopic evaluations by a pathologist; and IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. It offers DNA-based cancer diagnostics and services medical institutions. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also provides a range of non-proprietary oncology-focused tests and laboratory services that offer critical genomic information to healthcare professionals, as well as biopharma and biotech. The company was founded in 1999 and is headquartered in Rutherford, New Jersey.
Is CGIX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.2
52 Week Low 0.2
Average Volume 1,353,820
200-Day Moving Average 0.8101
50-Day Moving Average 0.3511
20-Day Moving Average 0.2985
10-Day Moving Average 0.3041
Average True Range 0.0722
ADX 25.15
+DI 27.171
-DI 20.3485
Chandelier Exit (Long, 3 ATRs ) 0.2334
Chandelier Exit (Short, 3 ATRs ) 0.4266
Upper Bollinger Band 0.4098
Lower Bollinger Band 0.1872
Percent B (%b) 0.43
BandWidth 74.572864
MACD Line -0.0213
MACD Signal Line -0.024
MACD Histogram 0.0027
Fundamentals Value
Market Cap 5.6 Million
Num Shares 19.8 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -0.28
Price-to-Sales 1.94
Price-to-Book 2.87
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.34
Resistance 3 (R3) 0.35 0.33 0.33
Resistance 2 (R2) 0.33 0.32 0.33 0.33
Resistance 1 (R1) 0.31 0.31 0.30 0.30 0.33
Pivot Point 0.29 0.29 0.29 0.29 0.29
Support 1 (S1) 0.27 0.28 0.26 0.26 0.24
Support 2 (S2) 0.26 0.27 0.25 0.24
Support 3 (S3) 0.23 0.26 0.23
Support 4 (S4) 0.22